ATNM · Actinium Pharmaceuticals, Inc.
$0.86
-0.03 (-2.94%)
At close · Jul 24
Market Cap
$26.98M
Shares
31.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.89
Open$0.91
Day$0.89–0.91
52W$0.88–1.89
Avg vol 30d113K
Short int820K · 2.6% float · 8.6d
Short vol63%
DataJan 2020–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−15%
below
RSI (14)
39
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−28%
trailing
YTD return
−34%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
4 of 55 funds reported for Jun 30 · net +190 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.61% of float · ▼ -12.5% MoM · 8.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
55 holders — near 3-yr low, contrarian setup
Squeeze score
48
elevated · 0–100
Fundamentals
Revenue growth
+11%
Y/Y
Gross margin
0%
EPS growth
+14%
Y/Y
Free cash flow
$-24.7M
Balance sheet
$47.1M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
39
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
4 of 55 funds reported for Jun 30 · net +190 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.61% of float · ▼ -12.5% MoM · 8.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
55 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $1 · 1%
52-wk high $2
vs 200-day avg -28%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATNM
this stock
Actinium Pharmaceuticals, Inc.
|
$26.98M | -34.5% | — | — | 2.6% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATNM | +0.1% | -11.8% | -27.6% | -9.1% | -34.5% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +1.8% | -12.5% | -33.9% | -7.9% | -42.7% |